Table 2 Lyso Gb3 levels and residual enzymatic activity after 1 year of ERT.

From: Effects of agalsidase-β administration on vascular function and blood pressure in familial Anderson–Fabry disease

 

Patient 1

Patient 2

Patient 3

Patient 4

Before ERT

After 1 year of ERT

Before ERT

After 1 year of ERT

Before ERT

After 1 year of ERT

Before ERT

After 1 year of ERT

Residual enzymatic activity

0

0.5

0

0.4

4.9

2.7

1

1.5

GL-3 (nMol/L)

46.8

16.5

64.7

18.4

5.8

2.6

7.7

2.7

  1. ERT enzyme replacement therapy, GL-3 globotriaosylceramide.
Back to article page